Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paltusotine
Therapeutic Area : Endocrinology
Study Phase : Phase III
Recipient : Crinetics Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Paltusotine is Crinetics’ investigational, orally available nonpeptide somatostatin receptor type 2 (SST2) agonist being evaluated as a treatment for acromegaly and neuroendocrine tumors (NETs), including NETs complicated by carcinoid syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $13.0 million
February 28, 2022
Lead Product(s) : Paltusotine
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Recipient : Crinetics Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Upacicalcet Sodium
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Kissei Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UPASITA® is administered by intravenous injection to dialysis patients through dialysis circuit and it is possible to adjust the dose and control the medication under the control of physicians or medical staffs.
Product Name : Upasita
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2021
Lead Product(s) : Upacicalcet Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Kissei Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SK-1403
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SK-1403 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperparathyroidism, Secondary.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 14, 2019
Lead Product(s) : SK-1403
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SK-1403
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SK-1403 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperparathyroidism, Secondary.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 13, 2018
Lead Product(s) : SK-1403
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SK-1403
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism
Details : SK-1403 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperparathyroidism, Secondary.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 21, 2017
Lead Product(s) : SK-1403
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SK-1405
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
Details : SK-1405 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pruritus.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 14, 2017
Lead Product(s) : SK-1405
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Details : SK-1404 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nocturia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2017
Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study
Details : 14-C SK-1404 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Nocturia.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
August 25, 2016
Lead Product(s) : 14-C SK-1405
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 14-C SK-1405 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pruritus.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
July 27, 2016
Lead Product(s) : 14-C SK-1405
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SK-1405
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects
Details : SK-1405 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pruritus.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 08, 2016
Lead Product(s) : SK-1405
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
